Cancer Genetics, Inc () CEO Jay Roberts tells Proactive the drug discovery and preclinical oncology and immuno-oncology services provider says he's 'excited about the vision and future' of the firm by focusing more on drug discovery and by strengthening its balance sheet.

Roberts says the firm is well positioned to carry through new strategic alternative activities to further strengthen its position in the industry.

Read the original:
Cancer Genetics CEO "excited about the vision and future" by being highly focused on drug discovery - Proactive Investors USA & Canada